RAG-01 is an innovative saRNA therapy designed to upregulate the p21 tumor suppressor gene, a key regulator of cell cycle progression that has been challenging to target with traditional therapies.

A propensity-score matched cohort study found a significantly reduced risk of recurrence of bladder cancer in patients who ...

Investigators employed artificial intelligence to characterize tissue samples of high-risk NMIBC that were likely to recur or progress after treatment with intravesical bacillus Calmette-Guérin (BCG).

Immunogenicity: the ability of a substance, such as a vaccine or antigen, to provoke an immune response in the body. TICE® BCG: a specific strain of BCG that has been used for intravesical ...

Cretostimogene is an oncolytic immunotherapy with dual mechanism of action: viral replication leading to tumor lysis and release of granulocyte-macrophage colony stimulating factor.

Ferring’s Adstiladrin became the first intravesical oncologic virus approved by the FDA for BCG-Unresponsive NMIBC CIS in 2023. Health Canada gave its approval a year earlier in 2022.

There are three types of intravesical immunotherapies for bladder cancer: BCG treatment is the most common immunotherapy for cancer and is often the first-line option for bladder cancer.

Recall that Anktiva plus BCG is one of two intravesical regimens for BCG-unresponsive disease. The other is Adstiladrin, a “non-replicating adenoviral vector-based gene therapy” that was ...